Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of IW-1701 in Healthy Subjects
NCT02572349Phase 1Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing IW-1701 with Placebo (2 arms). Primary endpoint: Assessment of the safety and tolerability of IW-1701 in healthy subjects via adverse events at 8 days. Started Oct 2015; status: completed.
02
Drugs
olinciguat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02572349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572349.